Saturday, February 17, 2018
UCLA Meyer & Renee Luskin Conference Center, UCLA Campus
Prostate cancer is the second most common solid organ malignancy diagnosed in men. Unlike other solid organ malignancies, the challenge in prostate cancer is to confidently identify men with moderate and high grade cancers who would benefit most from aggressive therapy and triage the rest to active surveillance. Uniquely among solid organ cancers, imaging has not been a traditional part of the workup for prostate cancer, which has relied instead on transrectal US-guided template biopsy. Over the past few years, MR imaging has emerged as the best imaging modality to detect, grade and stage prostate cancer and is considered a valuable biomarker. The course will focus on the evolving role of MR imaging in prostate cancer diagnosis, monitoring, targeted biopsy and in focal and whole gland therapy planning. We will review all relevant MR imaging components of prostate cancer, new molecular modalities such as PSMA PET and an update on prostate cancer biomarkers.
Target Audience
Radiologists, urologists, radiation and medical oncologists and primary care physicians interested in understanding prostate MR imaging and its applications for active surveillance, biopsy planning and acquisition, surgical planning and radiation planning and its role as a prostate biomarker
At the conclusion of this course, participants should be able to:
